A Phase 2/3 interventional study of Zinc amino acid chelate and Placebo in Short Stature, sponsored by Federal University of São Paulo. Completed. Open to participants aged 7 Years to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-12-24.
Sponsored by Federal University of São Paulo · Phase 2/3, Interventional, and Prevention
The purpose of this study is to measure the effect of weekly zinc supplementation on schoolchildren with growth deficit or normal stature.
Zinc is an important micronutrient for humans. Trials with zinc have shown positive effects of supplementation on growth, but there is still a lack of results on schoolchildren population. This Randomized Double-Blind Controlled Trial was design to measure the effect of weekly zinc supplementation on schoolchildren with growth deficit and normal stature. Schoolchildren were allocated into two homogeneous groups named Growth Deficit (HAZ \< -1,5 Z-score), and Normal Stature (HAZ between -1,0 and ±1,0 Z-score) and were randomly assigned to compose two exposed and two control groups to receive a supplement of 30mg of zinc amino acid chelate or placebo individually once a week, during 12 weeks. Children's heights were measured at the end of supplementation period and again after 12 weeks.
125 studies on the registry are indexed under Dwarfism; 19 are open to participants now.
This study's enrollment of 199 is above the median of 75 across 74 interventional studies indexed under Dwarfism.
Browse Dwarfism studies →Federal University of São Paulo is the lead sponsor of 427 studies on the registry; 22 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD). During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
Dietary Supplement: Zinc amino acid chelate
Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD). During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
Other: Placebo
For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex. During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
Other: Placebo
For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex. During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
Dietary Supplement: Zinc amino acid chelate
During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
Change in Height-for-Age Z-score (HAZ) From End of Supplementation to End of Follow-up Period.
Schoolchildren were allocated into two homogeneous groups named Growth Deficit (HAZ \< -1,5 Z-score), and Normal Height (HAZ between -1,0 and ±1,0 Z-score), and were randomly assigned to compose two exposed groups to receive a supplement of 30mg of zinc amino acid chelate, and two control groups to receive placebo individually once a week, during 12 weeks. Children's heights were measured at the End of Supplementation period and again after 12 weeks (Follow-up period). In combination with sex and age we transformed stature to Height-for-Age, expressed in Z-score, which was calculated as a number of standard deviations or Z-scores below or above the reference mean or median value, according to the formula below: Z-score = (observed value - median value of the reference population) / standard deviation value of reference population. We analyzed and discussed the change in HAZ (HAZ at the End of Follow-up period - HAZ at End of Supplementation).
Time frame: Height-for-Age Z-score was measured at the End of Supplementation period and again at the End of Follow-up period, with a 12 weeks interval.
From original database of 2.519 children, enrolled in the first and second grades of four State-run public basic schools, we selected this study sample using height for age indicator (HAZ). Meetings were held at school with parents/guardians to explain the objective and procedures of the study in order to obtain a written consent.
| Milestone | Growth Deficit+Zinc Amino Acid Chelate | Growth Deficit + Placebo | Normal Height+Zinc Amino Acid Chelate | Normal Height + Placebo |
|---|---|---|---|---|
| Started | 50 | 50 | 49 | 50 |
| Completed | 40 | 38 | 39 | 42 |
| Not completed | 10 | 12 | 10 | 8 |
| Withdrew: Transference or evasion of school | 7 | 9 | 7 | 6 |
| Withdrew: Adverse event | 2 | 0 | 1 | 0 |
| Withdrew: Refused to receive supplement | 1 | 0 | 1 | 0 |
| Withdrew: Less than 12 weeks supplementation | 0 | 3 | 1 | 2 |
| Milestone | Growth Deficit+Zinc Amino Acid Chelate | Growth Deficit + Placebo | Normal Height+Zinc Amino Acid Chelate | Normal Height + Placebo |
|---|---|---|---|---|
| Started | 40 | 38 | 39 | 42 |
| Completed | 27 | 18 | 24 | 30 |
| Not completed | 13 | 20 | 15 | 12 |
| Withdrew: Transference or evasion of school | 13 | 20 | 15 | 12 |
Schoolchildren were allocated into two homogeneous groups named Growth Deficit (HAZ \< -1,5 Z-score), and Normal Height (HAZ between -1,0 and ±1,0 Z-score), and were randomly assigned to compose two exposed groups to receive a supplement of 30mg of zinc amino acid chelate, and two control groups to receive placebo individually once a week, during 12 weeks. Children's heights were measured at the End of Supplementation period and again after 12 weeks (Follow-up period). In combination with sex and age we transformed stature to Height-for-Age, expressed in Z-score, which was calculated as a number of standard deviations or Z-scores below or above the reference mean or median value, according to the formula below: Z-score = (observed value - median value of the reference population) / standard deviation value of reference population. We analyzed and discussed the change in HAZ (HAZ at the End of Follow-up period - HAZ at End of Supplementation).
| Z-Score | Growth Deficit+Zinc Amino Acid Chelate | Growth Deficit + Placebo | Normal Height+Zinc Amino Acid Chelate | Normal Height + Placebo |
|---|---|---|---|---|
| Change in Height-for-Age Z-score (HAZ) From End of Supplementation to End of Follow-up Period. | 0.04 ± 0.12 | -0.08 ± 0.45 | 0.10 ± 0.15 | 0.02 ± 0.26 |
Collected over Adverse event data were collected during 12 weeks.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Growth Deficit+Zinc Amino Acid Chelate | — | 0/50 (0%) | 2/50 (4%) |
| Growth Deficit Receiving Placebo | — | 0/50 (0%) | 0/50 (0%) |
| Normal Height+Zinc Amino Acid Chelate | — | 0/49 (0%) | 1/49 (2%) |
| Normal Height Receiving Placebo | — | 0/50 (0%) | 0/50 (0%) |
| Event | Growth Deficit+Zinc Amino Acid Chelate | Growth Deficit Receiving Placebo | Normal Height+Zinc Amino Acid Chelate | Normal Height Receiving Placebo |
|---|---|---|---|---|
| Gastrointestinal eventGastrointestinal disorders | 2/50 | 0/50 | 1/49 | 0/50 |
| Age, Categorical(Participants) | Growth Deficit+Zinc Amino Acid Chelate | Growth Deficit + Placebo | Normal Height+Zinc Amino Acid Chelate | Normal Height + Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 50 | 50 | 49 | 50 | 199 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age Continuous(years) | Growth Deficit+Zinc Amino Acid Chelate | Growth Deficit + Placebo | Normal Height+Zinc Amino Acid Chelate | Normal Height + Placebo | Total |
|---|---|---|---|---|---|
| Mean | 7.63 ± 0.66 | 7.64 ± 0.71 | 7.63 ± 0.66 | 7.64 ± 0.71 | 7.63 ± 0.68 |
| Sex: Female, Male(Participants) | Growth Deficit+Zinc Amino Acid Chelate | Growth Deficit + Placebo | Normal Height+Zinc Amino Acid Chelate | Normal Height + Placebo | Total |
|---|---|---|---|---|---|
| Female | 25 | 25 | 24 | 25 | 99 |
| Male | 25 | 25 | 25 | 25 | 100 |
| Region of Enrollment(participants) | Growth Deficit+Zinc Amino Acid Chelate | Growth Deficit + Placebo | Normal Height+Zinc Amino Acid Chelate | Normal Height + Placebo | Total |
|---|---|---|---|---|---|
| Brazil | 50 | 50 | 49 | 50 | 199 |
No study locations are listed for this record.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Federal University of São Paulo